ABSTRACT OF THE DISCLOSURE

The invention provides a pharmaceutical formulation comprising:

(1) THAM, which is tris(hydroxymethyl)aminomethane, as a selective absorbefacient to enhance through the nasal mucosa-lined epithelium the absorption of substances of peptide nature; and

(2) a therapeutically effective amount of active nasal peptide, its pharmaceutically acceptable salt or its peptidic fragment;

in a pharmaceutically acceptable, aqueous liquid diluent or carrier, said formulation being in a form suitable for nasal administration.